Tradestie Institutional Equity Comparison Engine

REGN vs INSM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, REGN trades at 14.9x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus INSM at N/M Forward P/E and -41.7% operating margin (+268.4% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against INSM sits in CONSOLIDATION (38th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
REGN 14.9x vs INSM N/M Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs -41.7% ยท YoY +36.3% vs +268.4%
Momentum & Technical Winner REGN
1Y +27.3% vs -28.4% ยท 52W Pos 83% vs 44%
Options & Structure Winner REGN
CONSOLIDATION (6th %ile IV) vs CONSOLIDATION (38th %ile IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
INSM NASDAQ
Insmed, Inc.
Pharmaceutical Preparations
$144.46
+20.58% 1D
Market Cap $26.3B
1M Return +53.62%
1Y Return -28.35%
Forward P/E N/M
Unified AI Score
35.9 / 100 SELL
Tech 5.0 Fund 35.0 Flow 66.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +27.3% INSM -28.35% Spread: +55.65 pp (REGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period REGN Revenue INSM Revenue REGN Op. Margin INSM Op. Margin Margin Edge
FY2018 $5.15B $10M 49.3% -3124.9% REGN
FY2019 $6.56B $140M 33.7% -172.4% REGN
FY2020 $8.50B $160M 42.1% -161.3% REGN
FY2021 $16.1B $190M 55.7% -199.0% REGN
FY2022 $12.2B $250M 38.9% -186.4% REGN
FY2023 $13.1B $310M 30.9% -232.5% REGN
FY2024 $14.2B $360M 28.1% -241.5% REGN
FY2025 $14.3B $610M 24.9% -205.6% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (9) vs INSM (1)
Institutional Metric REGN INSM Criterion Row Winner
Market Capitalization Scale $97.8B $26.3B Larger Scale REGN
Trailing P/E Ratio Valuation 20.9x 107.5x Lower Multiple REGN
Forward P/E Ratio Valuation 14.9x N/M Lower Multiple REGN
Revenue Growth (YoY) Growth +36.3% +268.4% Higher Growth INSM
Operating Margin (TTM) Profitability 30.4% -41.7% Higher Margin REGN
Net Profit Margin Profitability 28.5% -39.9% Higher Margin REGN
Return on Equity (ROE) Capital Efficiency 14.9% -72.5% Higher ROE REGN
52-Week Range Position Momentum 83% ($592โ€“$992) 44% ($90โ€“$213) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.32ฮฒ ยท 55% Vol 0.40ฮฒ ยท 90% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 42.6 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite REGN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs INSM Buy Guide
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INSM CONSOLIDATION
72d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live INSM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor INSM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.